Iván R. González: Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

Iván R. González, Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla, shared on X:

“DRIATIC Study: Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.

Overall Survival:

Durvalumab: Median 55.9 months (95% CI, 37.3 to not reached)
Placebo: Median 33.4 months (95% CI, 25.5 to 39.9) HR for death: 0.73 (P=0.01)

Progression-Free Survival:

Durvalumab: Median 16.6 months (95% CI, 10.2 to 28.2)
Placebo: Median 9.2 months (95% CI, 7.4 to 12.9) HR for progression or death: 0.76 (P=0.02)

Adverse Events: Grade 3 or 4: 24.4% (durvalumab) vs 24.2% (placebo) Discontinuation: 16.4% (durvalumab) vs 10.6% (placebo)

Durvalumab significantly enhances both overall and progression-free survival compared to placebo in limited-stage small-cell lung cancer.”

Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer | NEJM

Authors: Ying Cheng, David R. Spigel, Byoung Chul Cho, Konstantin K. Laktionov, Jian Fang, Yuanbin Chen, Yoshitaka Zenke, Ki Hyeong Lee, Qiming Wang, Alejandro Navarro, Reyes Bernabe,  Eva Lotte Buchmeier, John Wen-Cheng Chang, Yoshimasa Shiraishi, Sema Sezgin Goksu, Andrzej Badzio, Anhui Shi, Davey B. Daniel, Nguyen Thi Thai Hoa, Milada Zemanova, Helen Mann, Hema Gowda, Haiyi Jiang, Suresh Senan,  for the ADRIATIC Investigators

Source: Iván R. González/X

More posts featuring Iván R. González on oncodaily.com